Fecal Immunochemical Test for Post-polypectomy Surveillance to Reduce Unnecessary eNdoscopy (FIT2RUN)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05396560 |
Recruitment Status :
Recruiting
First Posted : May 31, 2022
Last Update Posted : May 31, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease |
---|
Colorectal Neoplasms |
Colonoscopy is an effective tool in reducing colorectal cancer (CRC) incidence, however, it is a limited resource that is not without risk. The overall goal of this study is to determine if Fecal Immunochemical Tests (FIT) could be an effective alternative to colonoscopy for the surveillance of patients at increased risk for CRC. The rationale for this project is that colonoscopy is both a more expensive (30-40X) and more limited resource than FIT, which because of its pivotal role in the investigation and management of many gastrointestinal conditions is constantly in demand.
Routine post-polypectomy surveillance is placing a rapidly growing demand on existing colonoscopy resources, driven in part by the rapid expansion of CRC screening programs.(1) Currently, there are not strong contemporary data to guide the use of colonoscopy or alternative tests for the surveillance of patients after the removal of low or high risk polyps, but colonoscopy is routinely recommended by screening guidelines, as historically no other reasonable options existed. Colonoscopy screening is also the default recommendation for individuals with a family history of CRC or polyps.
It is proposed that the highly sensitive and low cost FIT could replace colonoscopy for post-polypectomy surveillance and primary screening in at least some patients and, thereby, reduce costs while improving access to colonoscopy for other patients.
The following knowledge gaps must be filled prior to advocating the use of FIT for post-polypectomy surveillance or primary screening:
- Contemporary data is lacking on the prevalence of advanced and non-advanced colorectal neoplasia at colonoscopy in a cohort of individuals with well characterized index pathology and/or family history of CRC/polyps.
- There is limited data on the sensitivity and specificity of FIT for the detection of advanced colorectal neoplasia in these settings.
- The factors that predict a higher risk of advanced colorectal neoplasia in those undergoing for post-polypectomy surveillance or a family history are unknown.
This is an observational study conducted in a clinical setting to estimate the prevalence of advanced colorectal neoplasia (ACN) at colonoscopy in those with a history of low or high risk polyps or a family history of CRC/polyps and to verify the test performance characteristics of FIT in these populations. Using this information, a risk prediction model will be developed to help guide the choice between FIT and colonoscopy in the ongoing surveillance or screening of patients.
Study Type : | Observational |
Estimated Enrollment : | 3000 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Official Title: | Fecal Immunochemical Test for Post-polypectomy Surveillance to Reduce Unnecessary eNdoscopy (FIT2RUN Study) |
Actual Study Start Date : | April 15, 2022 |
Estimated Primary Completion Date : | April 15, 2026 |
Estimated Study Completion Date : | April 15, 2027 |

- Advanced Colorectal Neoplasia (ACN) Prevalence [ Time Frame: At time of colonoscopy ]ACN: Colorectal cancer or an advanced adenoma (> 1 cm, villous features, high grade dysplasia) or serrated polyp (> 1 cm or any conventional dysplasia).
- Fecal Immunochemical Test Sensitivity and Specificity [ Time Frame: FIT test to be completed between 3-42 days prior to participant colonoscopy ]
Single fecal sample for measurement of hemoglobin using the OC-Sensor FIT. Positive if measured hemoglobin is ≥100 ng/ml (manufacturers recommended cut off).
Sensitivity = proportion of individuals with at least one ACN who had a positive FIT.
Specificity = proportion of individuals without advanced lesions who had a negative FIT.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 74 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- Men or women age ≤ 74 years of age.
-
At least one risk factor for CRC that would generally lead to colonoscopy screening:
- Personal history of low risk polyps
- Personal history of high risk polyps
- Family history of CRC or polyps
Exclusion Criteria:
- Known acromegaly, cystic fibrosis or high risk profession (firefighter)
- Referred for colonoscopy due to a positive fecal immunochemical test or CT colonography
- Known or suspected gene carrier for a familial cancer syndrome.
- Does not meet medical criteria for colonoscopy at the CCSC.
- Colonoscopy within the previous 30 months
- Unable to provide written informed consent or complete questionnaires due to language barrier or other reasons.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05396560
Contact: Robert Hilsden, MD PhD | 403-592-5089 | rhilsden@ucalgary.ca | |
Contact: Susanna Town, PhD | 403-592-5052 | susanna.town@ucalgary.ca |
Canada, Alberta | |
Forzani & Macphail Colon Cancer Screening Centre, University of Calgary | Recruiting |
Calgary, Alberta, Canada, T2N 4N1 | |
Contact: Robert Hilsden 1-403-592-5089 rhilsden@ucalgary.ca | |
Contact: Susanna Town 1-403-592-5052 susanna.town@ucalgary.ca |
Principal Investigator: | Robert Hilsden, MD PhD | University of Calgary |
Responsible Party: | University of Calgary |
ClinicalTrials.gov Identifier: | NCT05396560 |
Other Study ID Numbers: |
FIT2RUN01 |
First Posted: | May 31, 2022 Key Record Dates |
Last Update Posted: | May 31, 2022 |
Last Verified: | May 2022 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Undecided |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Colorectal Neoplasms Intestinal Neoplasms Gastrointestinal Neoplasms Digestive System Neoplasms Neoplasms by Site Neoplasms |
Digestive System Diseases Gastrointestinal Diseases Colonic Diseases Intestinal Diseases Rectal Diseases |